Lineage Cell Therapeutics, Inc. Income (Loss) from Equity Method Investments
Lineage Cell Therapeutics, Inc. (LCTX) reported Income (Loss) from Equity Method Investments of $0 for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-10.
Discontinued › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2018-03-15
- Lineage Cell Therapeutics, Inc. income (loss) from equity method investments for the quarter ending 2017-03-31 was $0.00.
- Lineage Cell Therapeutics, Inc. income (loss) from equity method investments for the quarter ending 2016-12-31 was -$3.48M.
- Lineage Cell Therapeutics, Inc. income (loss) from equity method investments for the quarter ending 2016-09-30 was -$855.00K.
- Lineage Cell Therapeutics, Inc. income (loss) from equity method investments for the quarter ending 2016-06-30 was -$98.00K.
- Lineage Cell Therapeutics, Inc. income (loss) from equity method investments for fiscal 2016 was -$4.67M.
- Lineage Cell Therapeutics, Inc. income (loss) from equity method investments for fiscal 2015 was -$35.00K.
- Lineage Cell Therapeutics, Inc. income (loss) from equity method investments for fiscal 2014 was $0.00.
- Lineage Cell Therapeutics, Inc. income (loss) from equity method investments for fiscal 2013 was $0.00.
| Period end | Income (Loss) from Equity Method Investments 3 month | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 9 month | Income (Loss) from Equity Method Investments 12 month |
|---|---|---|---|---|
| 2017-03-31 | $0.00 10-Q · filed 2017-05-10 | -$3.48M derived: sum of 2 quarters · filed 2018-03-15 | -$4.34M derived: sum of 3 quarters · filed 2018-03-15 | -$4.43M derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-12-31 | -$3.48M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | -$4.34M derived: sum of 2 quarters · filed 2018-03-15 | -$4.43M derived: sum of 3 quarters · filed 2018-03-15 | -$4.67M 10-K · filed 2018-03-15 |
| 2016-09-30 | -$855.00K 10-Q · filed 2016-11-04 | -$953.00K derived: sum of 2 quarters · filed 2016-11-04 | -$1.19M 10-Q · filed 2016-11-04 | -$1.22M derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-06-30 | -$98.00K 10-Q · filed 2016-08-09 | -$333.00K 10-Q · filed 2016-08-09 | -$368.00K derived: sum of 3 quarters · filed 2018-03-15 | -$368.00K derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-03-31 | -$235.00K 10-Q · filed 2017-05-10 | -$270.00K derived: sum of 2 quarters · filed 2018-03-15 | -$270.00K derived: sum of 3 quarters · filed 2018-03-15 | -$270.00K derived: sum of 4 quarters · filed 2018-03-15 |
| 2015-12-31 | -$35.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | -$35.00K derived: sum of 2 quarters · filed 2018-03-15 | -$35.00K derived: sum of 3 quarters · filed 2018-03-15 | -$35.00K 10-K · filed 2018-03-15 |
| 2015-09-30 | $0.00 10-Q · filed 2016-11-04 | $0.00 derived: sum of 2 quarters · filed 2016-11-04 | $0.00 10-Q · filed 2016-11-04 | |
| 2015-06-30 | $0.00 10-Q · filed 2016-08-09 | $0.00 10-Q · filed 2016-08-09 | ||
| 2015-03-31 | $0.00 10-Q · filed 2016-05-10 | |||
| 2014-12-31 | $0.00 10-K · filed 2017-03-16 | |||
| 2013-12-31 | $0.00 10-K · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |